Elite in Venous Thromboembolism (VTE)

Marc Carrier

Ottawa, ON, CA 
Elite in Venous Thromboembolism (VTE)
Ottawa, ON, CA 
OverviewLocationsClinical Research

Overview

Marc Carrier practices in Ottawa, Canada. Mr. Carrier is rated as an Elite expert by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are Venous Thromboembolism (VTE), Deep Vein Thrombosis, Mesenteric Venous Thrombosis, Heart Transplant, and Aortic Valve Replacement.

His clinical research consists of co-authoring 434 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 265 articles and participated in 3 clinical trials in the study of Venous Thromboembolism (VTE).

Gender
Male

Locations

Ottawa, ON, Canada
Other Locations
Laval, Canada
Laval, QC H7M3L9, Canada
Sault Ste. Marie, Barrie, ON, Canada
Toronto, ON, Canada
Hamilton, ON, Canada
Montreal, QC, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Drug
Study Drugs: Apixaban, Rivaroxaban
Study Phase: Phase 4
A Multicentre Prospective Cohort Study Assessing the Use of Weight-Adjusted Low-Molecular-Weight-Heparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism
A Multicentre Prospective Cohort Study Assessing the Use of Weight-Adjusted Low-Molecular-Weight-Heparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism
Enrollment Status: Terminated
Publish Date: January 23, 2024
Intervention Type: Biological
Study Drug: Dalteparin
Study Phase: Phase 2
D-dimer Testing, Tailored to Clinical Pretest Probability, to Minimize Initial and Follow-up Ultrasound Imaging in Suspected Deep Vein Thrombosis: A Management Study
D-dimer Testing, Tailored to Clinical Pretest Probability, to Minimize Initial and Follow-up Ultrasound Imaging in Suspected Deep Vein Thrombosis: A Management Study
Enrollment Status: Completed
Publish Date: September 28, 2021
A Multicenter Prospective Cohort Management Study to Evaluate the Safety of Withholding Anticoagulation in Patients With Subsegmental PE Who Have a Negative Serial Bilateral Lower Extremity Ultrasound
A Multicenter Prospective Cohort Management Study to Evaluate the Safety of Withholding Anticoagulation in Patients With Subsegmental PE Who Have a Negative Serial Bilateral Lower Extremity Ultrasound
Enrollment Status: Completed
Publish Date: May 28, 2021
A Multicentre Randomized Controlled Trial of the Use of Extended Peri-Operative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colorectal Cancer
A Multicentre Randomized Controlled Trial of the Use of Extended Peri-Operative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colorectal Cancer
Enrollment Status: Completed
Publish Date: May 17, 2021
Intervention Type: Drug
Study Drug: Tinzaparin
Study Phase: Phase 3
Perioperative Anticoagulant Use (Dabigatran, Rivaroxaban, or Apixaban) for Elective Surgery/Procedure Evaluation in Patients With Atrial Fibrillation (AF).
Perioperative Anticoagulant Use (Dabigatran, Rivaroxaban, or Apixaban) for Elective Surgery/Procedure Evaluation in Patients With Atrial Fibrillation (AF).
Enrollment Status: Completed
Publish Date: June 28, 2019
A Phase III, Multi-centre, Randomized Trial to Compare Rivaroxaban With Placebo for the Treatment of Symptomatic Leg Superficial Vein Thrombosis
A Phase III, Multi-centre, Randomized Trial to Compare Rivaroxaban With Placebo for the Treatment of Symptomatic Leg Superficial Vein Thrombosis
Enrollment Status: Completed
Publish Date: December 04, 2018
Intervention Type: Drug
Study Phase: Phase 3
Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients: A Randomized Placebo-Controlled, Double-Blind Clinical Trial
Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients: A Randomized Placebo-Controlled, Double-Blind Clinical Trial
Enrollment Status: Completed
Publish Date: November 20, 2018
Intervention Type: Drug
Study Phase: Phase 2
Age-adjusted D-dimer Cutoff Levels to Rule Out Deep Vein Thrombosis: a Prospective Outcome Study
Age-adjusted D-dimer Cutoff Levels to Rule Out Deep Vein Thrombosis: a Prospective Outcome Study
Enrollment Status: Unknown
Publish Date: October 01, 2018
Intervention Type: Other
Study Phase: Not Applicable
Contention Alone Versus Anticoagulation for Symptomatic Calf Vein Thrombosis Diagnosed by Ultrasonography
Contention Alone Versus Anticoagulation for Symptomatic Calf Vein Thrombosis Diagnosed by Ultrasonography
Enrollment Status: Completed
Publish Date: May 04, 2018
Intervention Type: Drug
Study Phase: Phase 3
Rivaroxaban in Antiphospholipid Syndrome Pilot Study: A Multicenter Feasibility Study of Rivaroxaban for Patients With Antiphospholipid Syndrome and Prior Arterial or Venous Thrombosis
Rivaroxaban in Antiphospholipid Syndrome Pilot Study: A Multicenter Feasibility Study of Rivaroxaban for Patients With Antiphospholipid Syndrome and Prior Arterial or Venous Thrombosis
Enrollment Status: Completed
Publish Date: October 18, 2017
Intervention Type: Drug
Study Phase: Phase 4
View 10 Less Clinical Trials

434 Total Publications

Apixaban for Cancer-Associated Venous Thromboembolism. Reply.
Apixaban for Cancer-Associated Venous Thromboembolism. Reply.
Journal: The New England journal of medicine
Published: July 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Carrier's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile